ENTITY
Hubei Biocause Pharmaceutical Co

Hubei Biocause Pharmaceutical Co (000627 CH)

5
Analysis
MaterialsChina
Hubei Biocause Pharmaceutical Co., Ltd. develops and produces pharmaceuticals focusing on the treatment of colonitis, high blood pressure, and infectious diseases. The Company also manufactures and markets carbinol and polypropylene chemical products.
more
29 May 2021 18:52

CSI300 Index Rebalance: 25 Changes as Long/Short Trade Does Well

There are 25 changes to the CSI300 Index that will be implemented at the close on 11 June. One-way turnover is 3.67% and the adds have outperformed...

Logo
494 Views
Share
14 Apr 2021 07:28

CSI300 Index Rebalance Preview: Recovering from the Growth Sell-Off

We forecast 30 changes to the CSI300 Index at the June review that will be announced at the end of May and effective 11 June. The expected...

Logo
409 Views
Share
16 Feb 2021 08:58

CSI300 Index Rebalance Preview: Maxing Out the Number of Changes

We see 30 potential inclusions/exclusions to the CSI300 index at the June review that will become effective COB 11 June. With a lot of benchmarked...

Logo
592 Views
Share
No more insights
x